T2 Biosystems (TTOO) Given News Impact Score of 0.17
Headlines about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. T2 Biosystems earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.5622133891327 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern’s rankings:
- T2 Biosystems (TTOO) Set to Announce Earnings on Tuesday (americanbankingnews.com)
- Investor’s Alert: ARMOUR Residential REIT, Inc. (NYSE:ARR), T2 Biosystems, Inc. (NASDAQ:TTOO) – The Oracle Examiner (oracleexaminer.com)
- T2 Biosystems Inc (TTOO) Stake Lowered by Fuller & Thaler Asset Management Inc. (americanbankingnews.com)
- Contrasting T2 Biosystems (TTOO) & Neogen (NEOG) (americanbankingnews.com)
- Uncover the Technical data on T2 Biosystems, Inc. (TTOO) – Wall Street Morning (wallstreetmorning.com)
A number of research firms have commented on TTOO. HC Wainwright set a $8.00 target price on T2 Biosystems and gave the company a “buy” rating in a research report on Monday, February 12th. Goldman Sachs Group began coverage on T2 Biosystems in a research report on Monday, January 29th. They issued a “neutral” rating and a $5.20 target price on the stock. Finally, Zacks Investment Research downgraded T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $5.56.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.